TABLE 4.

Baseline plasma homocysteine concentration in Heart Outcomes Prevention Evaluation (HOPE)-2 study participants^*

Region	Mean ± SD	Median	Interquartile range
Canada (n=2443)	11.80±4.59	11.00	9.1–11.3
United States (n=279)	11.72±5.21	10.70	9.0–12.8
Spain (n=62)	12.83±3.74	11.85	10.2–15.2
Sweden (n=124)	13.29±4.30	12.50	10.3–15.6
Austria (n=6)	12.02±1.76	11.65	11.4–13.8
Denmark (n=30)	13.46±6.73	12.45	9.2–15.7
Switzerland (n=26)	12.55±5.84	11.25	9.8–13.7
Slovakia (n=319)	14.54±6.55	13.30	10.6–16.4
Overall (n=3289)†	12.16±4.94	11.20	9.3–13.8

^*In μmol/L; plasma homocysteine was measured using the Abbott IMx method (Abbott Laboratories, Canada), which is based on fluorescence polarization immunoassay. The interassay imprecision for this method was less than 3.2% at all levels. Homocysteine data was not normally distributed

^†P<0.0001 for differences between countries